# Vaxinano

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxinano

- Industry: Biotechnology
- Headquarters: Loos, France
- Website: www.vaxinano.com
- Total disclosed funding: $6.6M
- Latest round: Seed (Oct 10, 2024)
- Investors on record: 5

## About

Vaxinano, based in France, focuses on developing innovative nasal vaccines and immunotherapies to combat zoonotic and infectious diseases, enhancing wildlife health through advanced solutions.Founded in 2016 and headquartered in Loos, France, Vaxinano specializes in producing nasal vaccines and immunotherapies. Didier Betbeder, the CEO and founder, has spearheaded the company's strategy without notable pivots. Vaxinano has completed 2 deals, with the most recent funding round occurring on October 10, 2024. They raised EUR 6.000 mn during a Seed round, which was supported by investors such as Bpifrance Investissement, Captech Health Nutrition, Nord France Amorçage, TCD Capital, and Wiseed, bringing the total amount raised to EUR 6.000 mn.Vaxinano specializes in developing nasal vaccines and immunotherapies aimed at zoonotic and infectious diseases. Their unique nanoparticle delivery system facilitates crossing mucosal barriers, promoting a swift immune response without adjuvants. The vaccines address challenging pathogens like parasites, viruses, and bacteria, focusing on conditions such as Toxoplasmosis and leishmaniasis. The company has formed partnerships with 24 zoos worldwide, targeting endangered species such as primates in their veterinary vaccine programs, and currently markets their products in various international regions needing advanced wildlife health solutions.Vaxinano’s revenue model is anchored in strategic partnerships with zoos and conservation organizations, where vaccinations are integrated into wildlife health programs. Collaborations with zoos enable tailored vaccination campaigns, supported by contractual agreements that typically cover supply and ongoing immunization support. Pricing varies based on campaign scale and client requirements, although specific figures are not disclosed. The company prioritizes fostering long-term partnerships, emphasizing the efficacy and safety of its veterinary health solutions.On October 10, 2024, Vaxinano raised EUR 6.000 mn in Seed funding to accelerate the development of vaccines and immunotherapies targeting leishmaniasis, toxoplasmosis, and colibacillosis. The company is focused on launching new products within these therapeutic areas. Future plans include expanding into additional international markets, although specific regions have not been disclosed. The recent funding will support these initiatives, enhancing their capacity to deliver innovative health solutions for wildlife.

## Funding rounds

- Seed, Oct 10, 2024, $6.6M — Wiseed, Bpifrance Investissement, Nord France Amorcage, TCD Capital, Captech Health Nutrition

## Investors

- Wiseed — Seed
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Seed
- Nord France Amorcage — Seed
- TCD Capital (https://capitalatlas.ai/funds/tcd-capital) — Seed
- Captech Health Nutrition — Seed